Rein Therapeutics, Inc.

About Rein Therapeutics, Inc.

Rein Therapeutics is dedicated to revolutionizing fibrosis care by introducing multi-pathway treatments. Their mission is to upend the standard of care in fibrosis, significantly improve patient outcomes, and ultimately end fibrosis through innovative therapies and comprehensive care approaches.

Products & Services

LTI-03:A groundbreaking therapy for Idiopathic Pulmonary Fibrosis (IPF) that aims to improve lung function, minimize side effects, and enhance quality of life with a dual-mechanism approach.

Dual-Mechanism Fibrotic Treatments:Pioneering multi-pathway therapies that operate at both anti-fibrotic and regenerative levels to reduce scarring and promote homeostasis, surpassing current standard care limitations.

LTI-03

Specialties

Fibrosis Care Multi-Pathway Therapies Dual-Mechanism Treatments Idiopathic Pulmonary Fibrosis (IPF) Treatment Multi-pathway Therapies Dual-mechanism Treatments Fibrosis Treatment Idiopathic Pulmonary Fibrosis (IPF) Anti-Fibrotic and Regenerative Therapies Multi-pathway fibrosis treatments IPF therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 57500000 MR: - FA: $57.5 million FAN: 57500000	D: 2026-05-18 FD: 2026-05-18	6 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2026-04-30 FD: 2026-04-30	1 investors
3	RT: Flexible Financing T: - FT: Flexible Financing	A: 21000000 MR: - FA: up to $21 million FAN: 21000000	D: 2025-07-30 FD: 2025-07-30	1 investors

Underwritten Public Offering Latest

2026-05-18

$57.5M

6 investors (Pro only)

Underwritten Public Offering 2026-04-30

$50.0M

Flexible Financing 2025-07-30

$21.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Brian Windsor

President and CEO

C

Cory Hogaboam

Chief Scientific Officer

T

Tim Cunningham

Interim Chief Financial Officer

K

Kristie Lauterbach

VP, Quality Assurance

M

Matt Karpen

VP, CMC

R

Ron Chen

VP, Finance and Corporate Controller

View 4 more team members with Pro

Unlock Full Team Directory

Recent News